Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells

被引:44
作者
Cerutti, A
Kim, EC
Shah, S
Schattner, EJ
Zan, H
Schaffer, A
Casali, P
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol, Div Mol Immunol, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, Dept Med, Div Hematol, New York, NY 10021 USA
关键词
D O I
10.1038/84254
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic lymphocytic leukemia (CLL) is associated with impaired immunoglobulin (Ig) class-switching from IgM to IgG and IgA, a defect that leads to recurrent infections,When activated in the presence of leukemic CLL B cells, T cells rapidly up-regulate CD30 through an OX40 ligand and interleukin 4 (IL-4)-dependent mechanism. These leukemia-induced CD30(+) T cells inhibit CD40 ligand (CD40L)-mediated S mu-->S gamma and S mu-->S alpha class-switch DNA recombination (CSR) by engaging CD30 ligand (CD30L), a molecule that interferes with the assembly of the CD40-tumor necrosis factor receptor-associated factor (TRAF) complex in nonmalignant IgD(+) B cells. In addition, engagement of T cell CD30 by CD30L on neoplastic CLL B cells down-regulates the CD3-induced expression of CD40L. These findings indicate that, in CLL, abnormal CD30-CD30L interaction impairs IgG and IgA production by interfering with the CD40-mediated differentiation of nonmalignant B cells.
引用
收藏
页码:150 / 156
页数:7
相关论文
共 51 条
[1]  
ADERKA D, 1993, BLOOD, V81, P2076
[2]   Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice [J].
Amakawa, R ;
Hakem, A ;
Kundig, TM ;
Matsuyama, T ;
Simard, JJL ;
Timms, E ;
Wakeham, A ;
Mittruecker, HW ;
Griesser, H ;
Takimoto, H ;
Schmits, R ;
Shahinian, A ;
Ohashi, PS ;
Penninger, JM ;
Mak, TW .
CELL, 1996, 84 (04) :551-562
[3]   TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: Transcriptional activation of I kappa B alpha [J].
Arsura, M ;
Wu, M ;
Sonenshein, GE .
IMMUNITY, 1996, 5 (01) :31-40
[4]   CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis [J].
Blair, PJ ;
Riley, JL ;
Harlan, DM ;
Abe, R ;
Tadaki, DK ;
Hoffmann, SC ;
White, L ;
Francomano, T ;
Perfetto, SJ ;
Kirk, AD ;
June, CH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :651-660
[5]  
BOWEN MA, 1993, J IMMUNOL, V151, P5896
[6]   Acquired CD40-ligand deficiency in chronic lymphocytic leukemia [J].
Cantwell, M ;
Hua, T ;
Pappas, J ;
Kipps, TJ .
NATURE MEDICINE, 1997, 3 (09) :984-989
[7]   CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells [J].
Cerutti, A ;
Schaffer, A ;
Shah, S ;
Zan, H ;
Liou, HC ;
Goodwin, RG ;
Casali, P .
IMMUNITY, 1998, 9 (02) :247-256
[8]   Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells [J].
Cerutti, A ;
Schaffer, A ;
Goodwin, RG ;
Shah, S ;
Zan, H ;
Ely, S ;
Casali, P .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :786-794
[9]   Phosphorylation of TRAF2 inhibits binding to the CD40 cytoplasmic domain [J].
Chaudhuri, A ;
Orme, S ;
Vo, T ;
Wang, WH ;
Cherayil, BJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 256 (03) :620-625
[10]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997